“LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT”. 2024. Mediterranean Journal of Hematology and Infectious Diseases 16 (1): e2024039. https://doi.org/10.4084/MJHID.2024.039.